Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study to Evaluate the Safety and Tolerability of the HCV Polymerase Inhibitor Pro-drug in Combination With Pegasys, With or Without Copegus, Versus Pegasys Plus Copegus, in Treatment-naïve Patients With Chronic Hepatitis C, Genotype 1

NCT00377182 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00377182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study to Evaluate the Safety and Tolerability of the HCV Polymerase Inhibitor Pro-drug in Combination With Pegasys, With or Without Copegus, Versus Pegasys Plus Copegus, in Treatment-naïve Patients With Chronic Hepatitis C, Genotype 1
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
August 31, 2008
Enrollment
107 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic